Encoded Therapeutics raised $275 million in Series F funding to advance ETX101, its one-time gene regulation therapy for SCN1A-positive Dravet syndrome, a rare and severe form of childhood epilepsy, into pivotal testing.
Investment Amount (In Millions): $275